The results of several retrospective studies have reported that systemic treatment in patients with psoriasis reduces the risk of incident psoriatic arthritis (PsA). Although encouraging from a prevention perspective, such studies are limited in their ability to provide a conclusive understanding of PsA risk, preventing a clear picture from emerging.
Subscription info for Chinese customers
We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Scher, J. U. et al. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat. Rev. Rheumatol. 15, 153–166 (2019).
Acosta Felquer, M. L. et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2021-220865 (2021).
Gisondi, P. et al. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2021-219961 (2021).
Shalev Rosenthal, Y. et al. Psoriatic arthritis incidence among patients receiving biologic medications for psoriasis: a nested case control study. Arthritis Rheumatol. https://doi.org/10.1002/art.41946 (2021).
Haberman, R. et al. Bridging the gaps in the care of psoriasis and psoriatic arthritis: the role of combined clinics. Curr. Rheumatol. Rep. 20, 76 (2018).
Ogdie, A. et al. Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study. Rheumatology https://doi.org/10.1093/rheumatology/keab622 (2021).
Ogdie, A. et al. Longitudinal analysis of the patient pathways to diagnosis of psoriatic arthritis. Arthritis Res. Ther. 23, 252 (2021).
Nguyen, U.-S. D. T. et al. Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study. Ann. Rheum. Dis. 77, 119–123 (2018).
Bell, S. et al. Aiming for cure and preventive initiatives in psoriatic disease: building synergy at NPF, GRAPPA, and PPACMAN. Curr. Rheumatol. Rep. 22, 78 (2020).
Hernan, M.A. & Robins, J. M. Causal Inference: What If (Boca Raton: Chapman & Hall, 2020).
The authors wish to acknowledge C. Ritchlin, J. Scher, J. Gelfand and the PAMPA study group dedicated to investigating opportunities in the prevention of psoriatic arthritis.
J.F.M. declares he is a consultant and/or investigator for Abbvie, Amgen, Biogen, BMS, Dermavant, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma and UCB. A.O. declares she has consulted for Abbvie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB and has received grants from Abbvie, Novartis and Pfizer to the University of Pennsylvania and Amgen to the Forward Databank. Her spouse has received royalties from Novartis.
About this article
Cite this article
Merola, J.F., Ogdie, A. Does psoriasis treatment affect PsA development?. Nat Rev Rheumatol 17, 708–709 (2021). https://doi.org/10.1038/s41584-021-00706-y